Soligenix appoints new VP of preclinical research and development

Soligenix, a Princeton, N.J.-based clinical stage biopharmaceutical company, recently announced the appointment of Oreola Donini to the position of vice president of preclinical research and development.

Donini is a co-inventor and leader of the SGX94 innate defense regulator technology, which was developed by Inimex Pharmaceuticals and later acquired by Soligenix. In preclinical studies, SGX94 demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to radiation, trauma, infections and chemotherapy treatment.

"As we continue to execute on our growth strategy, we are clearly building momentum and the talent we are attracting is an absolute reflection of our solid progress to date," Christopher Schaber, the president and CEO of Soligenix, said. "We are delighted to welcome Oreola to our team, as she will leverage her extensive preclinical and early stage clinical drug development expertise in leading our SGX94, gastrointestinal acute radiation syndrome and melioidosis programs. Her preclinical experience in the areas of infectious disease, tissue damage and innate immunity will be instrumental to us as we advance OrbeShield in GI ARS, and SGX94 to Phase II completion in oral mucositis."

Donini previously worked with ESSA Pharma Inc., Inimex Pharmaceuticals, Inc. and Kinetek Pharmaceuticals, Inc. in the development of novel therapies for cancer, infectious disease and cancer support care.

Soligenix develops products to treat serious inflammatory diseases, in addition to biodefense vaccines and therapeutics. Through the company's biodefense division, Soligenix is developing countermeasures for inclusion in the U.S. government's Strategic National Stockpile. Soligenix is developing OrbeShield for the treatment of gastrointestinal acute radiation syndrome under contracts with the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases.